Research
Economic value of gonorrhea resistance testing in the United States: A multi-perspective modeling study
PLOS ·
The Brief
- A multi-perspective modeling study assesses the economic value of gonorrhea resistance testing in the United States.
- Ceftriaxone is the only recommended first-line (empiric) treatment for gonorrhea, and rising antimicrobial resistance in Neisseria gonorrhoeae threatens its effectiveness.
- The study was published in PLOS Medicine on 2026-11-17 by Brooke E. Nichols, Betsy Wonderly Trainor, Grace Hampson, Yonatan H. Grad and Jeffrey D. Klausner.
Why it matters
Because ceftriaxone is the only recommended empiric therapy for gonorrhea, knowing whether resistance testing is economically worthwhile informs how clinics and health systems decide where to spend on diagnostics to preserve treatment options.
Who’s affected
- public health officials and policymakers working on US STI control
- clinicians and laboratories who manage gonorrhea testing and treatment
- #gonorrhea
- #antimicrobial resistance
- #ceftriaxone
- #sexually transmitted infections
- #health economics
- #diagnostic testing
by Brooke E. Nichols, Betsy Wonderly Trainor, Grace Hampson, Yonatan H. Grad, Jeffrey D. Klausner Background Rising antimicrobial resistance in Neisseria gonorrhoeae threatens the effectiveness of existing therapies. Ceftriaxone is the only recommended first-line (empiric)…